Annexin A2 and cancer: A systematic review

Christensen,Maria V.; Høgdall,Claus K.; Jochumsen,Kirsten M.; Høgdall,Estrid V.S.

doi:10.3892/ijo.2017.4197

Annexin A2 and cancer: A systematic review

Authors:
- Maria V. Christensen
- Claus K. Høgdall
- Kirsten M. Jochumsen
- Estrid V.S. Høgdall
View Affiliations

Affiliations: Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark, Department of Gynaecology, Juliane Maria Centre (JMC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, Department of Gynaecology and Obstetrics, Odense University Hospital, Odense, Denmark
Published online on: November 8, 2017 https://doi.org/10.3892/ijo.2017.4197
Pages: 5-18

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Annexin A2 is a 36-kDa protein interfering with multiple cellular processes especially in cancer progression. The present review aimed to show the relations between Annexin A2 and cancer. A systematic search for studies investigating cancer and Annexin A2 expression was conducted using PubMed. Acute lymphoblastic leukaemia, acute promyelocytic leukaemia, clear cell renal cell carcinoma, breast, cervical, colorectal, endometrial, gastric cancer, glioblastoma, hepatocellular carcinoma, lung, multiple myeloma, oesophageal squamous cell carcinoma, ovarian cancer, pancreatic duct adenocarcinoma, prostate cancer and urothelial carcinoma were evaluated. Annexin A2 expression correlates with resistance to treatment, binding to the bone marrow, histological grade and type, TNM-stage and shortened overall survival. The regulation of Annexin A2 is of interest due to its potential as target for a more individualized cancer management.

View Figures

View References

1	Gerke V and Moss SE: Annexins: From structure to function. Physiol Rev. 82:331–371. 2002. View Article : Google Scholar : PubMed/NCBI
2	Deora AB, Kreitzer G, Jacovina AT and Hajjar KA: An annexin 2 phosphorylation switch mediates 11-dependent translocation of annexin 2 to the cell surface. J Biol Chem. 279:43411–43418. 2004. View Article : Google Scholar : PubMed/NCBI
3	Wang CY and Lin CF: Annexin A2: Its molecular regulation and cellular expression in cancer development. Dis Markers. 2014:3089762014. View Article : Google Scholar : PubMed/NCBI
4	Filipenko NR and Waisman DM: The C terminus of annexin II mediates binding to F-actin. J Biol Chem. 276:5310–5315. 2001. View Article : Google Scholar
5	Kassam G, Manro A, Braat CE, Louie P, Fitzpatrick SL and Waisman DM: Characterization of the heparin binding properties of annexin II tetramer. J Biol Chem. 272:15093–15100. 1997. View Article : Google Scholar : PubMed/NCBI
6	Hajjar KA, Jacovina AT and Chacko J: An endothelial cell receptor for plasminogen/tissue plasminogen activator. I Identity with annexin II. J Biol Chem. 269:21191–21197. 1994.PubMed/NCBI
7	Sarafian T, Pradel LA, Henry JP, Aunis D and Bader MF: The participation of annexin II (calpactin I) in calcium-evoked exocytosis requires protein kinase C. J Cell Biol. 114:1135–1147. 1991. View Article : Google Scholar : PubMed/NCBI
8	Emans N, Gorvel JP, Walter C, Gerke V, Kellner R, Griffiths G and Gruenberg J: Annexin II is a major component of fusogenic endosomal vesicles. J Cell Biol. 120:1357–1369. 1993. View Article : Google Scholar : PubMed/NCBI
9	Babiychuk EB and Draeger A: Annexins in cell membrane dynamics. Ca²⁺-regulated association of lipid microdomains. J Cell Biol. 150:1113–1124. 2000. View Article : Google Scholar : PubMed/NCBI
10	Chiang Y, Rizzino A, Sibenaller ZA, Wold MS and Vishwanatha JK: Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol Cell Biochem. 199:139–147. 1999. View Article : Google Scholar : PubMed/NCBI
11	Oliferenko S, Paiha K, Harder T, Gerke V, Schwärzler C, Schwarz H, Beug H, Günthert U and Huber LA: Analysis of CD44-containing lipid rafts: Recruitment of annexin II and stabilization by the actin cytoskeleton. J Cell Biol. 146:843–854. 1999. View Article : Google Scholar : PubMed/NCBI
12	Huang Y, Yan CH and Fu SB: The cloning and expression of apoptosis associated gene ANNEXIN A2 induced by p53 gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 22:661–664. 2005.In Chinese. PubMed/NCBI
13	Waters KM, Stenoien DL, Sowa MB, von Neubeck C, Chrisler WB, Tan R, Sontag RL and Weber TJ: Annexin A2 modulates radiation-sensitive transcriptional programming and cell fate. Radiat Res. 179:53–61. 2013. View Article : Google Scholar
14	Coméra C, Rothhut B and Russo-Marie F: Identification and characterization of phospholipase A2 inhibitory proteins in human mononuclear cells. Eur J Biochem. 188:139–146. 1990. View Article : Google Scholar : PubMed/NCBI
15	Fan X, Krahling S, Smith D, Williamson P and Schlegel RA: Macrophage surface expression of annexins I and II in the phagocytosis of apoptotic lymphocytes. Mol Biol Cell. 15:2863–2872. 2004. View Article : Google Scholar : PubMed/NCBI
16	Choi KS, Fitzpatrick SL, Filipenko NR, Fogg DK, Kassam G, Magliocco AM and Waisman DM: Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer. J Biol Chem. 276:25212–25221. 2001. View Article : Google Scholar : PubMed/NCBI
17	Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH and Hajjar KA: Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest. 113:38–48. 2004. View Article : Google Scholar : PubMed/NCBI
18	Chen H, Xu C, Jin Q and Liu Z: S100 protein family in human cancer. Am J Cancer res. 4:89–115. 2014.PubMed/NCBI
19	Liu Y, Myrvang HK and Dekker IV: Annexin A2 complexes with S100 proteins: Structure, function and pharmacological manipulation. Br J Pharmacol. 172:1664–1676. 2015. View Article : Google Scholar :
20	Monastyrskaya K, Babiychuk EB, Hostettler A, Rescher U and Draeger A: Annexins as intracellular calcium sensors. Cell Calcium. 41:207–219. 2007. View Article : Google Scholar
21	Myrvang HK, Guo X, Li C and Dekker LV: Protein interactions between surface annexin A2 and S100A10 mediate adhesion of breast cancer cells to microvascular endothelial cells. FEBS Lett. 587:3210–3215. 2013. View Article : Google Scholar : PubMed/NCBI
22	Sharma MC and Sharma M: The role of annexin II in angiogenesis and tumor progression: A potential therapeutic target. Curr Pharm Des. 13:3568–3575. 2007. View Article : Google Scholar
23	Bolon I, Zhou HM, Charron Y, Wohlwend A and Vassalli JD: Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. Am J Pathol. 164:2299–2304. 2004. View Article : Google Scholar : PubMed/NCBI
24	Madureira PA, Bharadwaj AG, Bydoun M, Garant K, O'Connell P, Lee P and Waisman DM: Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10. Oncotarget. 7:47720–47737. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zhuang H, Tan M, Liu J, Hu Z, Liu D, Gao J, Zhu L and Lin B: Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells. Mol Cancer. 13:2432014. View Article : Google Scholar : PubMed/NCBI
26	Yang M and Huang CZ: Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. World J Gastroenterol. 21:11673–11679. 2015. View Article : Google Scholar : PubMed/NCBI
27	Sulzmaier FJ, Jean C and Schlaepfer DD: FAK in cancer: Mechanistic findings and clinical applications. Nat Rev Cancer. 14:598–610. 2014. View Article : Google Scholar : PubMed/NCBI
28	O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell. 79:315–328. 1994. View Article : Google Scholar : PubMed/NCBI
29	Wahl ML, Kenan DJ, Gonzalez-Gronow M and Pizzo SV: Angiostatin's molecular mechanism: Aspects of specificity and regulation elucidated. J Cell Biochem. 96:242–261. 2005. View Article : Google Scholar : PubMed/NCBI
30	Mai J, Waisman DM and Sloane BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta. 1477:215–230. 2000. View Article : Google Scholar : PubMed/NCBI
31	Mai J, Finley RL Jr, Waisman DM and Sloane BF: Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J Biol Chem. 275:12806–12812. 2000. View Article : Google Scholar : PubMed/NCBI
32	Roodman GD: Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev. 31:569–578. 2012. View Article : Google Scholar : PubMed/NCBI
33	Jung Y, Shiozawa Y, Wang J, Patel LR, Havens AM, Song J, Krebsbach PH, Roodman GD and Taichman RS: Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12 function in the hematopoietic stem cell endosteal niche. Exp Hematol. 39:151–166.e1. 2011. View Article : Google Scholar
34	Jung Y, Wang J, Lee E, McGee S, Berry JE, Yumoto K, Dai J, Keller ET, Shiozawa Y and Taichman RS: Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res. 13:197–207. 2015. View Article : Google Scholar :
35	D'Souza S, Kurihara N, Shiozawa Y, Joseph J, Taichman R, Galson DL and Roodman GD: Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood. 119:1888–1896. 2012. View Article : Google Scholar : PubMed/NCBI
36	Spijkers-Hagelstein JA, Mimoso Pinhanços S, Schneider P, Pieters R and Stam RW: Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia. 27:1063–1071. 2013. View Article : Google Scholar : PubMed/NCBI
37	Gopalakrishnapillai A, Kolb EA, Dhanan P, Mason RW, Napper A and Barwe SP: Disruption of Annexin II/p11 interaction suppresses leukemia cell Binding, homing and engraftment, and sensitizes the leukemia cells to chemotherapy. PLoS One. 10:e01405642015. View Article : Google Scholar
38	Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA and Hajjar KA: Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 340:994–1004. 1999. View Article : Google Scholar : PubMed/NCBI
39	Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D and Ruan C: The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res. 5:879–84. 2011. View Article : Google Scholar
40	Olwill SA, McGlynn H, Gilmore WS and Alexander HD: All-trans retinoic acid-induced downregulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia. Br J Haematol. 131:258–264. 2005. View Article : Google Scholar : PubMed/NCBI
41	Yang J, Cheng TT, Wang LN, Chen W and Li X: The expression and clinical significance of Annexin II in clear-cell renal cell carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 28:59–62. 2012.In Chinese. PubMed/NCBI
42	Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K and Tachibana M: Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer. 101:287–294. 2009. View Article : Google Scholar : PubMed/NCBI
43	Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP and Sharma MC: Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol. 81:146–156. 2006. View Article : Google Scholar : PubMed/NCBI
44	Shetty PK, Thamake SI, Biswas S, Johansson SL and Vishwanatha JK: Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer. PloS One. 7:442992012. View Article : Google Scholar
45	Sharma M, Blackman MR and Sharma MC: Antibody directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol. 92:175–184. 2012. View Article : Google Scholar
46	Jin L, Shen Q, Ding S, Jiang W, Jiang L and Zhu X: Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 126:140–146. 2012. View Article : Google Scholar : PubMed/NCBI
47	Choi CH, Chung JY, Chung EJ, Sears JD, Lee JW, Bae DS and Hewitt SM: Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer. BMC Cancer. 16:4482016. View Article : Google Scholar : PubMed/NCBI
48	Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R and Kast WM: The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PloS One. 7:e435192012. View Article : Google Scholar : PubMed/NCBI
49	Xiu D, Liu L, Qiao F, Yang H, Cui L and Liu G: Annexin A2 coordinates STAT3 to regulate the invasion and migration of colorectal cancer cells in vitro. Gastroenterol Res Pract. 2016:pp. 35214532016, https://doi.org/10.1155/2016/3521453. View Article : Google Scholar
50	Xing R, He H, He Y, Feng Y, Zhang C, Wu H, Sun M, Yu X, Liu Y, Song X, et al: ANXA2 remodels the microstructures of caco2 cells. Cell Mol Biol. 59(59 Suppl): OL1848–54. 2013.PubMed/NCBI
51	Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S and Nakajima Y: Annexin II overexpression correlates with stromal tenascin-C overexpression: A prognostic marker in colorectal carcinoma. Cancer. 92:1419–1426. 2001. View Article : Google Scholar : PubMed/NCBI
52	Tristante E, Martínez CM, Jiménez S, Mora L, Carballo F, Martínez-Lacaci I and de Torre-Minguela C: Association of a characteristic membrane pattern of annexin A2 with high invasiveness and nodal status in colon adenocarcinoma. Transl Res. 166:196–206. 2015. View Article : Google Scholar : PubMed/NCBI
53	Yang T, Peng H, Wang J, Yang J, Nice EC, Xie K and Huang C: Prognostic and diagnostic significance of annexin A2 in colorectal cancer. Colorectal Dis. 15:e373–e381. 2013. View Article : Google Scholar : PubMed/NCBI
54	Gurluler E, Guner OS, Tumay LV, Turkel Kucukmetin N, Hizli B and Zorluoglu A: Serum annexin A2 levels in patients with colon cancer in comparison to healthy controls and in relation to tumor pathology. Med Sci Monit. 20:1801–1807. 2014. View Article : Google Scholar : PubMed/NCBI
55	Deng L, Gao Y, Li X, Cai M, Wang H, Zhuang H, Tan M, Liu S, Hao Y and Lin B: Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma. J Exp Clin Cancer res. 34:962015. View Article : Google Scholar : PubMed/NCBI
56	Alonso-Alconada L, Santacana M, Garcia-Sanz P, Muinelo-Romay L, Colas E, Mirantes C, Monge M, Cueva J, Oliva E, Soslow RA, et al: Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. Int J Cancer. 136:1863–1873. 2015. View Article : Google Scholar
57	Zhang Q, Ye Z, Yang Q, He X, Wang H and Zhao Z: Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer. World J Surg Oncol. 10:1032012. View Article : Google Scholar : PubMed/NCBI
58	Han Y, Ye J, Dong Y, Xu Z and du Q: Expression and significance of annexin A2 in patients with gastric adenocarcinoma and the association with E-cadherin. Exp Ther Med. 10:549–554. 2015. View Article : Google Scholar : PubMed/NCBI
59	Gao H, Yu B, Yan Y, Shen J, Zhao S, Zhu J, Qin W and Gao Y: Correlation of expression levels of ANXA2, GAM1 and CALR with glioma grade and prognosis. J Neurosurg. 118:846–853. 2013. View Article : Google Scholar
60	Onishi M, Ichikawa T, Kurozumi K, Inoue S, Maruo T, Otani Y, Fujii K, Ishida J, Shimazu Y, Yoshida K, et al: Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma. Brain Tumor Pathol. 32:184–194. 2015. View Article : Google Scholar : PubMed/NCBI
61	Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR, Hajjar KA and Tsirka SE: Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci. 31:14346–14360. 2011. View Article : Google Scholar : PubMed/NCBI
62	Mohammad HS, Kurokohchi K, Yoneyama H, Tokuda M, Morishita A, Jian G, Shi L, Murota M, Tani J, Kato K, et al: Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol. 33:1157–1163. 2008.PubMed/NCBI
63	Bai DS, Wu C, Yang LX, Zhang C, Zhang PF, He YZ, Cai JB, Song ZJ, Dong ZR, Huang XY, et al: UBAP2 negatively regulates the invasion of hepatocellular carcinoma cell by ubiquitinating and degradating Annexin A2. Oncotarget. 7:32946–32955. 2016. View Article : Google Scholar : PubMed/NCBI
64	Zhang H, Yao M, Wu W, Qiu L, Sai W, Yang J, Zheng W, Huang J and Yao D: Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma. Tumour Biol. 36:9373–9383. 2015. View Article : Google Scholar : PubMed/NCBI
65	Zhang HJ, Yao DF, Yao M, Huang H, Wang L, Yan MJ, Yan XD, Gu X, Wu W and Lu SL: Annexin A2 silencing inhibits invasion, migration, and tumorigenic potential of hepatoma cells. World J Gastroenterol. 19:3792–3801. 2013. View Article : Google Scholar : PubMed/NCBI
66	Zhang HJ, Yao DF, Yao M, Huang H, Wu W, Yan MJ, Yan XD and Chen J: Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma. World J Gastroenterol. 18:5897–5904. 2012. View Article : Google Scholar : PubMed/NCBI
67	Cui HY, Wang SJ, Miao JY, Fu ZG, Feng F, Wu J, Yang XM, Chen ZN and Jiang JL: CD147 regulates cancer migration via direct interaction with Annexin A2 and DOCK3-β-catenin-WAVE2 signaling. Oncotarget. 7:5613–5629. 2016. View Article : Google Scholar
68	Dong Z, Yao M, Zhang H, Wang L, Huang H, Yan M, Wu W and Yao D: Inhibition of Annexin A2 gene transcription is a promising molecular target for hepatoma cell proliferation and metastasis. Oncol Lett. 7:28–34. 2014.
69	Sun Y, Gao G, Cai J, Wang Y, Qu X, He L, Liu F, Zhang Y, Lin K, Ma S, et al: Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis. 34:595–604. 2013. View Article : Google Scholar :
70	Wang YX, Lv H, Li ZX, Li C and Wu XY: Effect of shRNA mediated down-regulation of Annexin A2 on biological behavior of human lung adencarcinoma cells A549. Pathol Oncol Res. 18:183–190. 2012. View Article : Google Scholar
71	Jia JW, Li KL, Wu JX and Guo SL: Clinical significance of annexin II expression in human non-small cell lung cancer. Tumour Biol. 34:1767–1771. 2013. View Article : Google Scholar : PubMed/NCBI
72	Luo CH, Liu QQ, Zhang PF, Li MY, Chen ZC and Liu YF: Prognostic significance of annexin II expression in non-small cell lung cancer. Clin Transl Oncol. 15:938–946. 2013. View Article : Google Scholar : PubMed/NCBI
73	Cole SP, Pinkoski MJ, Bhardwaj G and Deeley RG: Elevated expression of annexin II (lipocortin II, 36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer. 65:498–502. 1992. View Article : Google Scholar : PubMed/NCBI
74	Bao H, Jiang M, Zhu M, Sheng F, Ruan J and Ruan C: Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol. 90:177–185. 2009. View Article : Google Scholar : PubMed/NCBI
75	Lokman NA, Pyragius CE, Ruszkiewicz A, Oehler MK and Ricciardelli C: Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. Transl Res. 171:83–95.e2. 2016. View Article : Google Scholar : PubMed/NCBI
76	Deng Y, Chen C, Hua M, Xi Q, Liu R, Yang S, Liu J, Zhong J, Tang M, Lu S, et al: Annexin A2 plays a critical role in epithelial ovarian cancer. Arch Gynecol Obstet. 292:175–182. 2015. View Article : Google Scholar
77	Lokman NA, Elder AS, Ween MP, Pyragius CE, Hoffmann P, Oehler MK and Ricciardelli C: Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget. 4:1199–1211. 2013. View Article : Google Scholar : PubMed/NCBI
78	Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein DG, Sood AK and Guo P: RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. Nanomedicine. 13:1183–1193. 2016. View Article : Google Scholar : PubMed/NCBI
79	Foley K, Rucki AA, Xiao Q, Zhou D, Leubner A, Mo G, Kleponis J, Wu AA, Sharma R, Jiang Q, et al: Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Sci Signal. 8:ra77. 2015. View Article : Google Scholar : PubMed/NCBI
80	Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT, et al: Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PloS One. 6:e193902011. View Article : Google Scholar : PubMed/NCBI
81	Nedjadi T, Kitteringham N, Campbell F, Jenkins RE, Park BK, Navarro P, Ashcroft F, Tepikin A, Neoptolemos JP and Costello E: S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer. 101:1145–1154. 2009. View Article : Google Scholar : PubMed/NCBI
82	Huang YK, Liu H, Wang XZ and Zhu S: Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma is associated with tumor recurrence and prognosis. Asian Pac J Cancer Prev. 15:9921–9926. 2014. View Article : Google Scholar : PubMed/NCBI
83	Jung H, Kim JS, Kim WK, Oh KJ, Kim JM, Lee HJ, Han BS, Kim DS, Seo YS, Lee SC, et al: Intracellular annexin A2 regulates NF-κB signaling by binding to the 50 subunit: Implications for gemcitabine resistance in pancreatic cancer. Cell Death Dis. 6:e16062015. View Article : Google Scholar
84	Takano S, Togawa A, Yoshitomi H, Shida T, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Tomonaga T, et al: Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol. 15:3157–3168. 2008. View Article : Google Scholar : PubMed/NCBI
85	Zheng L and Jaffee EM: Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy. OncoImmunology. 1:112–114. 2012. View Article : Google Scholar : PubMed/NCBI
86	Keklikoglou I, Hosaka K, Bender C, Bott A, Koerner C, Mitra D, Will R, Woerner A, Muenstermann E, Wilhelm H, et al: MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KrAs genes. Oncogene. 34:4867–4878. 2015. View Article : Google Scholar :
87	Zhang Q, Zhao Z, Ma Y, Wang H, Ma J, He X and Zhang D: Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma. Urol Oncol. 32:798–805. 2014. View Article : Google Scholar : PubMed/NCBI
88	Feng JG, Liu Q, Qin X, Geng YH, Zheng ST, Liu T, Sheyhidin I and Lu XM: Clinicopathological pattern and Annexin A2 and CDC42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas. Mol Biol Rep. 39:1267–1274. 2012. View Article : Google Scholar
89	Li X, Zheng S, Liu Q, Liu T, Liang M, Gao X, Lu M, Sheyhidin I and Lu X: Under-expression of annexin A2 is associated with Kazakh's esophageal squamous cell carcinoma. Mol Carcinog. 54:779–788. 2015. View Article : Google Scholar
90	Rodrigo Tapia JP, Pena Alonso E, García-Pedrero JM, Florentino Fresno M, Suárez Nieto C, Owen Morgan R and Fernández MP: Annexin A2 expression in head and neck squamous cell carcinoma. Acta Otorrinolaringol Esp. 58:257–262. 2007.In Spanish. View Article : Google Scholar : PubMed/NCBI
91	Yee DS, Narula N, Ramzy I, Boker J, Ahlering TE, Skarecky DW and Ornstein DK: Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Arch Pathol Lab Med. 131:902–908. 2007.PubMed/NCBI
92	Ding T, Yang L, Wang Y, Yuan J, Chen T and Cai X: Downregulation of annexin II in prostate cancer is associated with Gleason score, recurrence, metastasis and poor prognosis. Mol Med Rep. 3:781–787. 2010.
93	Smitherman AB, Mohler JL, Maygarden SJ and Ornstein DK: Expression of annexin I, II and VII proteins in androgen stimulated and recurrent prostate cancer. J Urol. 171:916–920. 2004. View Article : Google Scholar : PubMed/NCBI
94	Sharma M, Blackman MR and Sharma MC: Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol. 92:175–184. 2012. View Article : Google Scholar
95	Singh P, Wu H, Clark C and Owlia A: Annexin II binds progastrin and gastrin-like peptides, and mediates growth factor effects of autocrine and exogenous gastrins on colon cancer and intestinal epithelial cells. Oncogene. 26:425–440. 2007. View Article : Google Scholar
96	Reeves SA, Chavez-Kappel C, Davis R, Rosenblum M and Israel MA: Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res. 52:6871–6876. 1992.PubMed/NCBI
97	Zhong LP, Wei KJ, Yang X, Zhang L, Zhou XJ, Pan HY, Li J, Chen WT and Zhang ZY: Increased expression of Annexin A2 in oral squamous cell carcinoma. Arch Oral Biol. 54:17–25. 2009. View Article : Google Scholar
98	Sharma MC, Tuszynski GP, Blackman MR and Sharma M: Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer. Cancer Lett. 373:27–35. 2016. View Article : Google Scholar : PubMed/NCBI